Efficacy of once-daily Avelox for complicated abdominal infections highlighted at ICAAC

SAN FRANCISCO, Sept. 29, 2006 The efficacy of monotherapy with the once-daily, broad-spectrum antibiotic AVELOX (moxifloxacin HCl) in the treatment of complicated intra-abdominal infections (cIAI) was highlighted in two clinical data presentations by researchers here at the 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 2006, Schering-Plough Corporation (NYSE: SGP) reported today.

Approximately 3.5 million Americans are diagnosed annually with cIAIs, which are caused by disease, trauma or surgery in the abdomen that can allow bacteria to leak from the gastrointestinal tract into adjacent tissue.(1)

"Complicated intra-abdominal infections often involve several different kinds of bacteria and require broad-spectrum antibiotic therapy for effective treatment," said Robert J. Spiegel, M.D., chief medical officer and senior vice president, Schering-Plough Research Institute. "The data presented at ICAAC further underscore the efficacy of once-daily AVELOX monotherapy in treating these infections."

AVELOX is the only marketed fluoroquinolone antibiotic approved by the U.S. Food and Drug Administration (FDA) as monotherapy to treat cIAI, and has been shown to be effective at eradicating the most common bacteria that cause cIAI, including E. coli and B. fragilis. AVELOX is indicated to treat polymicrobial cIAI infections, including infections caused by mixed aerobic and anaerobic bacteria (bacteria that thrive without oxygen) commonly seen in patients with cIAI.(2,3)


Contact: Trista Dawson
GCI Group

Page: 1

Related biology news :

1. Malaria: Efficacy of monotherapies in Cameroon
2. Avelox as effective as Levofloxacin combination therapy for severe community-acquired pneumonia
3. FDA approves AVELOX (moxifloxacin HCl) for treatment of complicated intra-abdominal infections
4. Hepatitis C complicated by morphine withdrawal
5. The simple truth: Animal development not as complicated as it seems
6. Scientists find that the human nose is more complicated than a jumbo jet
7. AVELOX as effective as multi-dose combination therapy for intra-abdominal infections
8. New research suggests abdominal aortic aneurysm will afflict millions of baby boomers
9. MRI excellent choice for overcoming challenges of diagnosing pregnant women with abdominal pain
10. Pets could be source of multiresistant bacteria infections in humans, MU researchers investigate
11. Injection drug use and HIV and HCV infections among Ontario prison inmates

Post Your Comments:

(Date:6/23/2020)... ... June 23, 2020 , ... In its June 22 online post, ... Dr. James L. Sherley, M.D., Ph.D., founder and director of stem cell biotechnology company ... on June 16 that starting July 5 it would begin offering free ...
(Date:6/11/2020)... ... 08, 2020 , ... Cryo-Cell International’s announcement comes on the ... in the medical field. The face masks will be distributed nationwide to obstetrical ... day to provide healthcare to pregnant women. The delivery of masks is scheduled ...
(Date:6/2/2020)... ... June 02, 2020 , ... ... software developer and solutions provider, today reported that the implementation of browser-based, ... compliance by 100%, resulting in greater efficiency for global biotechnology company, bioMérieux. ...
Breaking Biology News(10 mins):
(Date:7/31/2020)... SOMERSET, N.J (PRWEB) , ... July 29, 2020 ... ... editing company, and Catalent, the leading global provider of advanced delivery technologies, development, ... products, today announced that they have entered into a strategic partnership whereby Catalent ...
(Date:7/31/2020)... ... , ... The SDX® Respiratory Gating System , trusted ... its 20th anniversary of worldwide use. Introduced in the US over the past ... of Pennsylvania, University of Michigan, University of Maryland, University of California San Francisco—and ...
(Date:7/22/2020)... ... July 22, 2020 , ... Join experts from Reed Tech ... Regulatory Solutions, in a one hour live webinar on Thursday, August 13, ... China for drugs and medical devices. Specifically, for medical devices, the NMPA has departments ...
(Date:7/18/2020)... (PRWEB) , ... July 16, 2020 , ... “We are ... Third Wave Bioactives. “It’s the only technology of its kind on the market and ... of onions with the protective capacity of traditional cultured ingredients, creating a natural way ...
Breaking Biology Technology:
Cached News: